Glaxo Appoints Top Scientist to Board Ahead of Company Split
- Genetics specialist will become non-exec at revamped pharma
- Activist investor Elliott has been pushing for such hires
Photographer: Simon Dawson/Bloomberg
This article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
GlaxoSmithKline Plc appointed a top geneticist to the board of its new-look pharmaceutical and vaccines company, as the under pressure British drugmaker moves to beef up the scientific expertise on its top panel ahead of its split next year.